Tango Therapeutics to Highlight Preclinical Data on
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida. Abstract titles, presentation information and text, if provided by the meeting organizers, are currently available on the AACR 2023 Annual Meeting website.
Abstracts accepted for oral presentation
Title: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models
Abstract #: 3452
Session title: Novel Antitumor Agents and Targets
Presenter: Kimberly Briggs, Ph.D., Associate Director, Tango Therapeutics
Session Date and Time: April 17, 2023, 2:30-4:30 p.m. ET
TNG908 is brain penetrant in non-human primates, suggesting the potential for clinical efficacy in MTAP-deleted glioblastoma (GBM). Oral administration of TNG908 is efficacious in MTAP-deleted xenograft models across histologies, including GBM. TNG908 treatment increased median survival by three-fold in a murine GBM orthotopic model compared to controls. TNG908 is being studied in an ongoing Phase 1/2 trial for patients with MTAP-deleted tumors, including those with GBM.
Title: TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers
Session Title: New Drugs on the Horizon Session: Part 3
Presenter: Leanne Ahronian, Ph.D., Senior Scientist, Tango Therapeutics
Session Date and Time: April 17, 2023, 10:15-11:45 a.m. ET
Abstracts accepted for poster presentation
Title: Characterization of the clinical development candidate TNG348 as a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut cancers
Abstract #: 4968
Format: Poster Presentation
Session Title: Novel Targets and Pathways
Session Date and Time: April 18, 2023, 1:30-5:00 p.m. ET
Title: TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors
Abstract #: 4970
Format: Poster Presentation
Session Title: Novel Targets and Pathways
Session Date and Time: April 18, 2023, 1:30-5:00 p.m. ET
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), expectations, beliefs and development objectives for Tango’s product pipeline and clinical trials. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, statements concerning the following include or constitute forward-looking statements: TNG908 isbrain penetrant in non-human primates, suggesting the potential for clinical efficacy in glioblastoma; TNG260 will be studied in a phase 1/2 trial of STK11 mutant cancers in combination with a checkpoint inhibitor; TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors; the expected benefits of the Company's development candidates and other product candidates; and the expected timing of: (i) development candidate declaration for certain targets, (ii) initiating IND-enabling studies; (iii) filing INDs; (iv) clinical trial initiation and (v) disclosing initial and final clinical trial results. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Tango has limited experience conducting clinical trials and may not be able to commence the clinical trial (including opening clinical trial sites and enrolling and dosing an adequate number of clinical trial participants) when expected and may not generate results (including final or initial safety and efficacy data) in the anticipated timeframe (or at all); benefits of product candidates seen in preclinical analyses may not be evident when tested in clinical trials or when used in broader patient populations (if approved for commercial sale); the benefits of Tango pipeline products, development candidates and potential combination therapies that are seen in pre-clinical experiments may not be present in clinical trials or in use commercially or may not be safe and/or effective in humans; Tango has a limited operating history and has not generated any revenue to date from product sales, and may never become profitable; other companies may be able to identify and develop product candidates more quickly than the Company and commercially introduce the product prior to the Company; the Company’s proprietary discovery platform is novel and may not identify any synthetic lethal targets for future development; the Company may not be able to identify development candidates on the schedule it anticipates due to technical, financial or other reasons; the Company may not be able to file INDs for development candidates on time, or at all, due to technical or financial reasons or otherwise; the Company may utilize cash resources more quickly than anticipated; Tango will need to raise capital in the future and if we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our development programs or future commercialization efforts; we may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience significant delays in doing so as a result of factors beyond Tango’s control; Tango’s approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; Tango may not identify or discover additional product candidates or may expend limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; our products candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay or prevent regulatory approval; our dependence on third parties for conducting clinical trials and producing drug product; our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad; and delays and other impacts on product development and clinical trials from the COVID-19 pandemic. Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the SEC, including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.
Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media Contact:
Amanda Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com

TIN LIÊN QUAN
Sana Biotechnology Announces the Acceptance of Four
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene...
Mablink Bioscience to Present Promising Preclinical Data
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with...
Notice of the Annual General Meeting 2023 of Copenhagen
Notice is hereby given of the Annual General Meeting of Copenhagen Airports A/S to be held on Thursday, 30 March 2023 at 3:00 pm. The notice, including...
Beam Therapeutics to Participate in the 43rd Annual Cowen
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...
MEDIA ADVISORY: ONTARIO ENGLISH CATHOLIC TEACHERS’
Saturday, March 11 – Monday, March 13, 2023...
Itaú Corpbanca Files Material Event Notice to Summoning to
SANTIAGO, Chile, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ITAÚ CORPBANCA (NYSE: ITCB; SSE: ITAUCORP) today announced that it filed a Material Event Notice with...
Lyra Therapeutics Announces Appointment of John Bishop,
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...
Molecular Partners to Present at SVB Leerink Global
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
THỦ THUẬT HAY
3 cách để bảo vệ toàn diện trên môi trường Internet
Vấn đề bảo mật khi dùng Internet luôn là một trong những điều mà người dùng quan tâm nhất, nhưng dữ liệu của bạn rất dễ bị rò rỉ và bán cho những nhà quảng cáo, do đó, hôm nay, TCN sẽ giới thiệu cho các bạn ba công cụ
12 ứng dụng dành cho Android đang miễn phí và giảm giá
Tiếp tục cập nhật danh sách 'Free App' hằng ngày dành cho smartphone Android, TCN đã tổng hợp thêm khá nhiều ứng dụng và game trả phí đang được miễn phí. Nếu bạn quan tâm hãy nhanh tay tải về trước khi bị tính phí trở
3 cách sử dụng camera OPPO Reno6 Pro 5G để có những video siêu chất
Hôm nay chúng ta hãy nói đến camera, cách sử dụng camera OPPO Reno6 Pro 5G để tạo ra những đoạn video siêu phẩm cực kì ấn tượng và đẹp mắt.
Người dùng sắp có thể download trực tiếp các bộ font và gói ngôn ngữ trên Microsoft Store
Quan sát phần mô tả các bạn sẽ thấy bộ font này tương thích với các rất nhiều thiết bị từ PC, Mobile, Hub tới Holo Lens nhưng lại yêu cầu thiết bị được cài đặt phiên bản Windows 10 Version 17040 hoặc cao hơn.
Hướng dẫn gọi video Facebook trên máy tính
Trong những bài viết trước, Quản Trị Mạng đã giới thiệu với các bạn cách gọi video - Video Call trên Facebook bằng máy tính, smartphone, máy tính bảng. Và lần này là video hướng dẫn trực quan để các bạn tiện theo dõi.
ĐÁNH GIÁ NHANH
Đánh giá chi tiết iPhone 13 – Camera và pin được nâng cấp, hiệu năng vượt trội
iPhone 13 ra mắt với nhiều nâng cấp và cải tiến so với thế hệ trước. Nổi bật trong đó phải kể đến hiệu năng, camera và pin. Trong bài đánh giá chi tiết iPhone 13 dưới đây, mình sẽ chỉ ra từng cải tiến Apple đã áp dụng
Tổng hợp tips hay nhất định phải biết để làm quen Galaxy Z Fold3 5G với tốc độ ánh sáng
Nếu bạn mới tậu về cho mình một chiếc Galaxy Z Fold3 5G mới và còn rất nhiều điều thú vị cần khám phá thì nhất định không thể bỏ qua bộ tips cực kỳ thiết thực dưới đây. Galaxy Z Fold3 5G ra đời đã mở ra một kỷ nguyên
So sánh iPad 10.2 2021 và iPad 10.2 2020: Có điểm gì khác biệt, có nên nâng cấp?
Ngày 14/9 vừa qua Apple đã giới thiệu iPad thế hệ 9 với mức giá hợp lý và iPad mini 6. Nếu iPad mini 6 tập trung vào thiết kế thì iPad 10.2 2021 lại được nâng cấp về phần cứng và tính năng. Vậy giữa phiên bản 2021 và